Results 171 to 180 of about 119,167 (297)

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

JGH Open
Hyder A, Alria A, Rafiq A, Akram MF, Hassan T, Ali EF, Vhora F, Khan S, Zahra SG, Niazi MA, Jafar U, Cheema HA, Alsubari AMA, Altaf F, Bhat A, Rashad E, Jalal PK.   +16 more
europepmc   +1 more source

Reduced‐Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate whether reduced‐frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy. Methods This retrospective case series included 30 adults who achieved weight plateau while on weekly
Michelle Wong, Ash Wu, Pawanjot K. Garhe, Mitch Biermann   +3 more
wiley   +1 more source

Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome. [PDF]

JCI Insight
Kudo Y, Miyamoto K, Suzuki S, Chida A, Tojo A, Hasegawa M, Shigehara A, Koya I, Ando Y, Sato M, Kondo A, Kumagai T, Deguchi H, Sugiyama Y, Ito Y, Shirosaki K, Yamagishi S, Maeda Y, Kanamori H, Kano M, Kato M, Tsujikawa H, Yoshimatsu Y, Takabayashi K, Okabayashi K, Kanai T, Hosoe N, Kato M, Moody J, Hon CC, Kuroda T, Yamada Y, Fujino A, Sujino T.   +33 more
europepmc   +1 more source

Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial. [PDF]

JPEN J Parenter Enteral Nutr, 2023
Naimi RM, Hvistendahl MK, Poulsen SS, Kissow H, Pedersen J, Nerup NA, Ambrus R, Achiam MP, Svendsen LB, Jeppesen PB.   +9 more
europepmc   +1 more source

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

Obesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

Commentary: a comparison of glucagon‐like peptides 1 and 2 [PDF]

Alimentary Pharmacology & Therapeutics, 2012
Moran, G.W., Lal, S., McLaughlin, J.T.
openaire   +3 more sources

Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models

Obesity, EarlyView.
ABSTRACT Objective/Methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP‐1 receptor agonist retatrutide in diet‐induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
François Briand, Camille Le Cudennec, Estelle Grasset, Natalia Breyner, Claire Bigot, Pierre Dillard, Thierry Sulpice   +6 more
wiley   +1 more source

Glucagon-Like Peptide-2 as a Potential Biomarker for Nonalcoholic Fatty Liver Disease in Children with Obesity: Preliminary Assessment of Metabolic Associations and Underlying Mechanisms. [PDF]

Diabetes Metab Syndr Obes
Zhang SJ, Xu K, Zhu F, Teng YQ, Tang YF, Xu HW.   +5 more
europepmc   +1 more source

Glucagon-Like Peptide 2¹ [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2001
openaire   +1 more source